The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics
Honoraria - Janssen
Consulting or Advisory Role - Beigene; Fortis; Janssen Oncology; Tolero Pharmaceuticals
Research Funding - Janssen (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Janssen
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - AstraZeneca; Janssen
Research Funding - Abbvie; Cancer Targeted Technology; Janssen; Merck; Novartis; Xynomic Pharma; Zenith Epigenetics
Travel, Accommodations, Expenses - Xynomic Pharma
 
Verena Friedl
No Relationships to Disclose
 
Alana Weinstein
No Relationships to Disclose
 
George V. Thomas
Consulting or Advisory Role - Auron Therapeutics
Patents, Royalties, Other Intellectual Property - Patensts t UCLA and OHSU (Inst)
 
Lawrence D. True
Stock and Other Ownership Interests - Lightspeed Microscopy
Research Funding - Ventana Medical Systems
Patents, Royalties, Other Intellectual Property - Lens on an open-top lightsheet microscope
 
Adam Foye
No Relationships to Disclose
 
Tomasz M. Beer
Stock and Other Ownership Interests - Arvinas; Salarius Pharmaceuticals
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; Janssen; Janssen Biotech; Merck; Pfizer
Research Funding - Alliance Foundation Trials (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Janssen Research & Development (Inst); Medivation/Astellas (Inst); Oncogenex (Inst); Sotio; Sotio (Inst); Theraclone Sciences (Inst)
 
Matthew Rettig
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
Martin Gleave
Stock and Other Ownership Interests - OncoGenex
Honoraria - Astellas Pharma; Bayer; Genova Diagnostics; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genova Diagnostics; Janssen; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bayer; Janssen
Patents, Royalties, Other Intellectual Property - OncoGenex - OGX-011, OGX-427; ST-CP; ST-POP
 
Christopher P. Evans
Stock and Other Ownership Interests - Exelixis
Honoraria - Astellas Pharma; Janssen Oncology; Pfizer
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology; MDxHealth
Speakers' Bureau - Astellas Pharma; Janssen Oncology; MDXHealth; Pfizer
Research Funding - Astellas Pharma; Ferring; Pfizer; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology
 
Joshi J. Alumkal
Consulting or Advisory Role - Janssen Biotech
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Gilead Sciences (Inst); Novartis (Inst); Zenith Epigenetics (Inst)
 
Robert Evan Reiter
Stock and Other Ownership Interests - ImaginAb
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Genomic Health; ImaginAb; Janssen Oncology
Patents, Royalties, Other Intellectual Property - patents surrounding discovery of PSCA and N-cadherin, owned by UCLA (Inst)
 
Primo Lara
Consulting or Advisory Role - CellMax Life; Foundation Medicine; Janssen; Merck
Research Funding - Aragon Pharmaceuticals (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); TRACON Pharma (Inst)
 
Kim N. Chi
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; ESSA; Janssen; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
 
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - Nutcracker Therapeutics, Inc.; PFS Genomics; SerImmune
Honoraria - Genentech
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Celgene; EMD Serono; Genzyme; Janssen Biotech; Medivation/Astellas
Research Funding - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Adina Bailey
No Relationships to Disclose
 
Josh Stuart
Employment - NantWorks (I)
Stock and Other Ownership Interests - NantWorks
 
Jiaoti Huang
No Relationships to Disclose